IN8bio sets new ATM stock program with JonesTrading
IN8bio, Inc. has put a new at-the-market stock offering program in place and ended its prior one.
Rhea-AI Filing Summary
IN8bio, Inc. has put a new at-the-market stock offering program in place and ended its prior one. On June 1, 2026, the company entered into a Capital on Sales Agreement with JonesTrading Institutional Services, allowing IN8bio to issue and sell common stock from time to time at its sole discretion under its existing Form S-3 shelf registration. JonesTrading will use commercially reasonable efforts to sell any shares and will earn a 3.0% commission on gross sales proceeds, while IN8bio has no obligation to sell any stock and either party can terminate the agreement on written notice.
The company also terminated its earlier Controlled Equity Sales Agreement with Cantor Fitzgerald & Co., effective May 29, 2026. Both parties waived the original advance notice requirements, and IN8bio is not subject to any termination penalties. After this termination, no additional shares may be issued or sold under the Cantor agreement or its related prospectus.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 1.01, 1.02, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 1.02
Termination of a Material Definitive Agreement
Business
A significant contract was terminated, which may affect business operations or revenue.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Sales commission to agent: 3.0% of gross sales proceeds
JonesTrading termination notice period: 10 days
Original Cantor termination notice period: 5 days
+2 more
5 metrics
Sales commission to agent
3.0% of gross sales proceeds
Commission on placement shares sold under JonesTrading agreement
JonesTrading termination notice period
10 days
Either party may terminate Capital on Sales Agreement on 10 days’ written notice
Original Cantor termination notice period
5 days
Five days’ written notice requirement under Sections 12(b) and 12(c), later waived
Cantor agreement termination date
May 29, 2026
Effective termination date of Controlled Equity Sales Agreement with Cantor
JonesTrading agreement date
June 1, 2026
Date IN8bio entered Capital on Sales Agreement with JonesTrading
Key Terms
at the market offering, Capital on Sales Agreement, Controlled Equity Sales Agreement, registration statement on Form S-3, +1 more
5 terms
at the market offering financial
"an at the market offering program under which the Company may issue and sell"
An at-the-market offering is a way a company raises cash by selling newly issued shares directly into the open market at prevailing prices, rather than all at once in a single deal. Think of it like turning a faucet on to drip shares into trading at current prices when needed; it gives the company flexibility to raise funds over time but can dilute existing shareholders and potentially affect the stock price, which investors should monitor.
Capital on Sales Agreement financial
"entered into a Capital on Sales Agreement (the “Sales Agreement”) with JonesTrading"
Controlled Equity Sales Agreement financial
"entered into a Controlled Equity Sales Agreement with Cantor Fitzgerald & Co."
registration statement on Form S-3 regulatory
"will be made pursuant to the Company’s registration statement on Form S-3"
A registration statement on Form S‑3 is a short, standardized filing a qualified public company uses to register new securities with regulators so they can be sold to investors; think of it as a pre-approved, reusable permission slip that speeds up future offerings. It matters to investors because it lets the company raise money more quickly and cheaply — which can fund growth or pay debt — but may also lead to share dilution or change in ownership, so it affects value and liquidity.
Emerging growth company regulatory
"Emerging growth company On June 1, 2026, IN8bio, Inc."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What did IN8bio (INAB) announce in this 8-K filing?
IN8bio entered a new at-the-market stock offering arrangement with JonesTrading and terminated its prior equity sales agreement with Cantor Fitzgerald, reshaping how it may raise equity capital under its existing Form S-3 shelf registration statement.
How does IN8bio’s new at-the-market program with JonesTrading work?
Under the Capital on Sales Agreement, IN8bio may, at its discretion, direct JonesTrading to sell common stock from time to time in at-the-market transactions under its S-3 registration. JonesTrading uses commercially reasonable efforts to execute sales based on the company’s instructions.
What fees will IN8bio pay JonesTrading under the new agreement?
IN8bio will pay JonesTrading a commission equal to 3.0% of the gross sales proceeds from any common stock sold through the at-the-market program. This fee applies only to shares actually sold under the Capital on Sales Agreement.
When was IN8bio’s prior Cantor equity sales agreement terminated?
The Controlled Equity Sales Agreement with Cantor Fitzgerald was mutually terminated effective at the close of business on May 29, 2026. Both parties waived the original five-day notice requirements, and IN8bio incurred no termination penalties in connection with ending that arrangement.
Can IN8bio still sell stock under the terminated Cantor agreement?
No. Following termination of the Controlled Equity Sales Agreement with Cantor Fitzgerald, IN8bio may not issue or sell any additional shares of common stock under that agreement or the related prospectus filed with its earlier shelf registration statement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
